Pharmacotherapy of nonnutritive sweeteners in diabetes mellitus

International Journal of Diabetes and Metabolism

Volumn 23, Issue 1, 2015, Pages 11-12

  Bastaki, Salim ^a  

^a UNITED ARAB EMIRATES UNIVERSITY   (United Arab Emirates)

Author keywords

Diabetes Mellitus; Nonnutritive sweeteners; Pharmacotherapy

Indexed keywords

ACESULFAME; ADVANTAME; ALITAME; ASPARTAME; CYCLAMATE SODIUM; FRUCTOSE; NEOTAME; NONNUTRITIVE SWEETENER; SACCHARIN; STEVIOSIDE; SUCRALOSE; TAGATOSE; UNCLASSIFIED DRUG;

ARTICLE; DIABETES MELLITUS; HUMAN; LIFESTYLE MODIFICATION; NONHUMAN; PROPHYLAXIS; STEVIA; SYMPTOM; TOXICITY TESTING;

EID: 84947447034     PISSN: 16067754     EISSN: 20735944     Source Type: Journal    
DOI: 10.1159/000497734     Document Type: Article

References (162)

1. Amos A, McCarty D, Zimmet P. The rising global burden of diabetes and its complications, estimates and projections to the year 2010. Diabetic Med 1997; 14: S1-S85.
2. King H, Aubert R, Herman W. Global burden of diabetes, 1995-2025. Prevalence, numerical estimates and projections. Diabetic Care 1998; 21: 1414-1431.
3. Zimmet P. Globalization, coca-colonization and the chronic disease epidemic: can the Doomsday scenario be averted? J Med 2000; 247: 301-310.
4. Kumar PJ, Clark M. Textbook of Clinical Medicine. Pub: Saunders (London), pp 1099-1121, 2002.
5. Zimmet PZ, McCarty DJ, de Courten MP. The global epidemiology of non-insulin-dependent diabetes mellitus and the metabolic syndrome. J Diabetes Complications 1997; 11: 60-68.
6. Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the expert committee on the diagnosis and classification of Diabetes Mellitus. Diabetes Care 1997; 20: 1183-1197.
7. Lindberg G, Lindblad U, Melander A. Sulfonylureas for treating type 2 diabetes mellitus. Cochrane Database Systemic Reviews volume 3, 2004.
8. Jones CN, Abbasi F, Carantoni M, Polonsky KS, Reaven GM. Roles of insulin resistance and obesity in regulation of plasma insulin concentration. Am J Physiol Endocrinol Metab 2000; 278: E501-E508.
9. Aarsland A, Chinkes D, Wolfe RR. Contribution of de novo synthesis of fatty acids to total VLDL-triglyceride secretion during prolonged hypergly-cemia/hyperinsulinemia in normal man. J Clin Invest 1996; 98: 2008-2017.
10. Kahn SE. The importance of the beta-cell in the pathogenesis of type 2 diabetes mellitus. Am J Med 2000; 106 (suppl 6a): 2S-8S.
11. Lόpez-Ibarra PJ, Pastor MM, Escobar-Jiménez F, et al. Bone mineral density at time of clinical diagnosis of adult-onset type 1 diabetes mellitus. Endoc Pract 2001; 7: 346-351.
12. Ishida H1, Seino Y, Taminato T, Usami M, Takeshita N, Seino Y, et al: Circulating levels and bone contents of bone gamma-carboxyglutamic acid-containing `proteins are decreased in streptozotocin-induced diabetes: possible market for diabetic osteopenia. Diabetes 1988; 37: 702-706.
13. Bearse MA Jr, Han T, Schneck ME, Barez S, Jacobsen C, Adams AJ. Local multifocal oscillatory potential abnormalities in diabetes and early diabetic retinopathy. Invest Ophthal 2004; 45: 3259-3265.
14. Hove MN, Kristensen JK, Lauritzen T, Bek T. The prevalence of retinopathy in an unselected population of type 2 diabetes patients from Arhus County, Denmark. Acta Ophthalmologica Scandinavica 2004; 82: 443-448.
15. Seki M, Tanaka T, Nawa H, Usui T, Fukuchi T, Ikeda K, Abe H, Takei N. Involvement of brain-derived neurotrophic factor in early retinal neuropathy of streptozotocin-induced diabetes in rats: therapeutic potential of brain-derived neurotrophic factors for dopaminergic amacrine cells. Diabetes 2004; 53: 2412-2419.
16. Moran A, Palmas W, Field L, Bhattarai J, Schwartz JE, Weinstock RS, Shea S. Cardiovascular autonomic neuropathy is associated with microalbuminuria in older patients with type 2 diabetes. Diabetes care 2004; 27: 972-977.
17. Huang C, Kim Y, Caramori ML, Fish AJ, Rich SS, Miller ME, et al. Cellular basis of diabetic nephropathy: II. The transforming growth factor-beta system and diabetic nephropathy lesions in type 1 diabetes. Diabetes 2002; 51: 3577-3581.
18. Shukla N, Angelini GD, Jeremy JY, Looker HC, Fagot-Campagna A, Gunter EW, et al. Homocysteine as a risk factor for nephropathy and retinopathy in type 2 diabetes. Diabetologia 2003; 46; 766-772.
19. Svensson M, Eriksson JW, Dahlquist G. Early glycemic control, age at onset, and development of microvascular complications in childhood-onset type 1 diabetes: a population-based study in northern Sweden. Diabetes Care 2004; 27: 955-962.
20. Saely CH, Aczel S, Marte T, Langer P, Drexel H. Cardiovascular complications in type 2 diabetes mellitus depend on the coronary angiographic state rather than on the diabetes state. Diabetologia 2004; 47: 145-146.
21. Wallace C, Reiber GE, LeMaster J, Smith DG, Sullivan K, Hayes S, et al. Incidence of falls, risk factors for falls, and fall-related factures in individuals with diabetes and a prior foot ulcer. Diabetes Care 2002; 25: 1983-1986.
22. Centers for Disease Control and Prevention (CDCP). History of foot ulcer among persons with diabetes-Unites States, 2000-2002. Morbidity & Mortality Weekly Report. 2003; 52: 1098-1102.
23. Sekikawa A1, Tominaga M, Takahashi K, Eguchi H, Igarashi M, Ohnuma H, et al: Prevalence of diabetes and impaired glucose tolerance in Funagata area in Japan. Diabetes Care 1993; 16: 570-574.
24. Ramachandran A1, Snehalatha C, Latha E, Vijay V, Viswanathan M.. Rising prevalence of NIDDM in an urban population in India. Diabetologia 1997; 40: 232-237.
25. O’Dea K. Marked improvement in carbohydrate and lipid metabolism in diabetic Australian Aborigines after temporary reversion to traditional lifestyle. Diabetes 1984; 33: 596-603.
26. Pan XR, Li GW, Hu YH, Wang JX, Yang WY, An ZX, et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and Diabetes Study. Diabetic Care 1997; 20: 537-544.
27. Eriksson KF, Lindgarde F. Prevention of type 2 (Non-insulin-dependent) diabetes mellitus by diet and physical exercise: 6-year Malmo feasibility study. Diabetologia 1991; 34: 891-898.
28. Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, et al. Reduction in the incident of type 2 diabetes with lifestyle intervention or metformin. N Eng J Med 2002; 346: 393-403.
29. Watkins PJ, Drury PL, Taylor KW. An Overview of management. In: diabetes and its Management. ED Blackwell Scientific Publication; fourth edition, 1990; pp 63-66.
30. Bastaki S. Diabetes and its treatment. Review. Int J Diabetes Metabolism 2005; 13: 111-134.
31. National Institutes of Health. Diabetes in America, 2nd edn. Bethesda, MD: National Institutes of Health, 1995. (NIH Publication no. 95-1468.)
32. Mann JI and Lewis-Barned NJ. Dietary management of diabetes mellitus in Europe and North America. In: International Textbook of Diabetes Mellitus third ed. Vol. 1 Ed. RA Defronzo, E Ferrannini, H Keen, P Zimmet, 2004, pp725-739.
33. Born P, Eimiller A, Paul F. High rate of gastrointestinal side effects in fructose-consuming patients. Diabetes Care 1987; 10: 376-377.
34. Bright G. Low-calorie sweeteners-from molecules to mass markets. World Rev Nutr Diet 1999; 85: 3-9.
35. Armstrong B, Doll R. Bladder cancer mortality in England and Wales in relation to cigarette smoking and saccharin consumption. Br J Prev Soc Med 1974; 28: 233-240.
36. Armstrong B, Doll R. Bladder cancer mortality in diabetics in relation to saccharin consumption and smoking habits. Br J Prev Soc Med 1975; 29: 73-81.
37. Taylor JM, Weinberger MA, Friedman L. Chronic toxicity and carcinogenecity to the urinary bladder of sodium saccharin in the utero-exposed rat. Toxicol Appl Pharmacol 1980; 54: 225-252.
38. Squire RA. Histopathological evaluation of rat urinary bladders from the IRDC two-generation bioassay of sodium saccharin. Food Chem Toxicol 1985; 23: 491-497.
39. “All about sucralose”. (Http://www.sucralose.org/ facts/default.asp).
40. Calorie Control Council..http://www.sucralose.org/facts/default.asp.
41. Brown AW, Brown MMB, Onken KL, Beitz DC. Short-term consumption of sucralose, a nonnutritive sweetener, is similar to water with regard to select markers of hunger signaling and short-term glucose homeostasis in women. Nut Res 2011; 31: 882-888.
42. Friedman MA, Lead Deputy Commissioner for the FDA, Food Additives Permitted for Direct Addition to Food for human Consumption; sucralose (http://www.fda.gov/ohrms/dockets/98fr/040398a.pdf) Federal Register: 21 CFR Part 172, Docket No. 87F-0086, April 3, 1998.
43. Knight I. The development and application of sucralose, a new high-intensity sweetener. Can J Physiol Pharmacol 1994; 72: 435-439.
44. Grotz VL, Henry RR, McGill JB, Prince MJ, Shamoon H, Trout JR, et al. Lack of effect of sucralose on glucose homeostasis in subjects with type 2 diabetes. J Am Diet Assoc 2003; 103: 1607-1612.
45. “Strong Clinical Database that supports Safety of Splenda Sweetener Products” (http://www.splenda. com/page.jhtml?id+=splenda/newspromotions/press/safety.inc.).
46. McNeil Nutritionals. L.L.C. http://www.splenda.com/page/jhtml?id=splenda/newspromotion /press/safety.inc. Retrieved 2009-12-30.
47. Food and Drug Administration. “Food labeling: health claims; dietary noncariogenic carbohydrate sweeteners and dental caries”. Federal Register 2006: 71: 15559-15564.
48. A 12-week study of the effect of sucralose on glucose homeostasis and HbA1c in normal healthy volunteers, Centre for Food Safety and Applied Nutrition, U.S. FDA. FAP 7A3987, August 16, 1996, pp. 1-357.
49. Ford HE, Peters V, Martin NM, Sleeth ML, Ghatei MA, Frost GS, et al. Effects of oral ingestion of sucralose on gut hormone response and appetite in healthy normal-weight subjects. Eur J Clin Nutr 2011; 65: 508-513.
50. Acceptable intake of sweeteners Canadian Diabetes Association. http://www.diabetes.ca /cpg2003/chap-ters.aspx?table1acceptabledailyintakeofsweeteners.htm.
51. Goldsmith LA. Acute and subchronic toxicity of sucralose. Food Chem Toxicol 2000; 38 (suppl 2): S53-S69.
52. Genevieve, F. Sucralose: An Overview (http://www. kon.org/urc/frank.html). Penn State University.
53. Grotz VL, Munro IC. An overview of the safety of sucralose. Regul Toxicol Pharmacol 2009; 55: 1-5. PMID 19464334.
54. Grice HC, Goldsmith LA. Sucralose-an overview of the toxicity data. Food Chem Toxicol 2000; 38 (suppl 2): S1-6.PMID 10882813.
55. Baird IM, Shepard NW, Merritt RJ, Hildick-Smith, G. Repeated dose study of sucralose tolerance in human subjects. Food Chem Toxicol 2000; 38 (suppl 2): S123-S129.
56. Labare MP, Alexander M, Biodegradation of sucralose in samples of natural environments. Environ Toxicol Chem 1993; 12: 797-804.
57. Measurements of sucralose in the Swedish Screening Program. Part 1; Sucralose in surface waters and STP samples (http://www.naturavards verket.se)
58. Wiklund AK, Breitholtz M, Bengtsson BE, Adolfsson-Erici M. Sucralose-An ecological challenger? Chemosphere 2012; 86: 50-55. Epub 2011, Sep 28.
59. Flamm WG, Blackburn GL, Comer CP, Mayhew DA, Stargel WW. Long-term food consumption and body weight changes in neotame safety studies are consistent with the allometric relationship observed for other sweeteners and during dietary restrictions. Regul Toxicol Pharmacol 2003; 38: 1440156.
60. Patel RM, Sarma R, Grimsley E. Popular sweetener sucralose as a migraine trigger, Headache 2006; 46: 1303-1304.
61. Bigal ME, Krymchantowski AV. Migraine triggered by sucralose-a case report. Headache 2006; 46: 515-517.
62. Geuns JMC. Stevioside. Phytochemistry 2003; 64: 913-921.
63. Ramesh K, Singh V, Megeji NW. Cultivation of stevia (Stevia rebaudiana Bertoni): A comprehensive review. Adv Agron 2006; 89: 137-177.
64. Hanson JR, De Oliveira BH. Stevioside and related sweet diterpenoid glycosides. Nat Prod Rep 1993; 10: 301-309.
65. Definition of Stevia. Merriam Webster. http://www.merriam-webster.com/dictionary/stevia.
66. Parsons WT, Cuthbertson EG. Noxious Weeds of Australia. 2nd ed. 2001, Collingwood. Australia: CSIRO Publishing. ISBN 978-0-643-06514-7. This reference refers to Stevia eupatoria, a related weed having the same nomenclature origin.
67. Opinion on Stevia rebaudiana plants and leaves. European Commission Scientific Committee on Food. 17 June 1999.
68. Misra H, Soni M, Silawat N, Mehta D, Mehta BK, Jain DC. Antidiabetic activity of medium-polar extract from the leaves of Stevia rebaudiana Bert. (Bertoni) on alloxan-induced diabetic rats. J Pharm Bioallied Sci, 2011; 3: 242-248.
69. Kinghorn AD, Soejarto DD. Discovery of terpenoid and phenolic sweeteners from plants. Pure Appl Chem 2002; 74: 1169-1179.
70. Bertoni, MS. Revista de Agronomia de l’Assomption, 1899; 1: 35.
71. Bridel M, Laviella R. Sur le principe sucre des feuilles de Kaa-he-e (stevia rebaudiana B). Academie des Sciences Paris Comptes Rendus 1931; (parts 192): 1123-1125.
72. Crammer B, Ikan R. Sweet glycosides from the stevia plant. Chem Br, 1986; 22(10): 915-917.
73. Kim J, Choi CH, Choi CH. Stevia, the genus Stevia. Medicinal and Aromatic Plants-industrial Profiles. In: A.D. Kinghorn (ed.), Use of Stevioside and Cultivation of Stevia rebaudiana in Korea 2002; Vol 19. Tailor and Francis, London pp. 196-202.
74. Mizutani K, Tanaka O. Stevia, the genus Stevia. Medicinal and Aromatic Plants-Industrial Profiles. In: Use of Stevioside and Cultivation of Stevia rebaudiana in Korea 2002; Vol 19. Tailor and Francis, London pp. 178-195.
75. Geuns JMC. Review: The safety of Stevioside used as sweetener. In: J.M.C. Geuns, J.G. Buyse (eds), Proc 1st symposium: the safety of Stevioside. KULeuven, April 16th 2004, Euprint ed., Parkbosstraat #, 3001, Hervelee, pp. 85-127.
76. Brandle JE, Starratt, AN, Giizen M. Stevia rebaudiana: Its biological, chemical and agricultural properties. Retrieved June 28, 2000, from http://res2.agr.ca/london/pmc/faq/stevia_rev.html.
77. Kinghorn AD, Soejarto DD. Current status of stevioside as a sweetening agent for human use. In: H. Wagner, H. Hikino, & N.R. Fansworth (Eds.), Economic and Medical Plant Research 1985; Vol 1 (pp. 1-52), London, Academic Press.
78. Brandle JE, Rosa N. Heritability for yield, leaf: stem ratio and stevioside content estimated from a landrace cultivator of Stevia rebaudiana. Retrieved June 28, 2000, from http://res2.agr.ca/london/pmc/faq/cjps-ste.html.
79. Choi YH, Kim I, Yoon KD, Lee SJ, Kim CY, Yoo KP., et al. Supercritical fluid extraction and liquid chromatographic-electrospray mass spectrometric analysis of stevioside from Stevia rebaudiana leaves. Chromatographia 2002; 55: 617-620.
80. Joint FAO/WHO Expert Committee on Food Additives (JECFA), steviol glycosides in Combined Compendium of Food Additives Specifications, 68th Meeting of the Joint FAO/WHO Expert Committee on Food Additives (Online Edition), FAO/JECFA Monograph 4, Rome: Food and Agricultural Organization of the United Nations (FAO), Rome, Italy 2007, pp. 61-64.
81. Jeppesen PB, Gregersen S, Poulsen CR, Hermansen K. Stevioside acts directly on pancreatic β cells to secrete insulin: actions independent of cyclic adenosine monophosphate and adenosine triphosphate-sensitive K+-channel activity. Metabolism 2000; 49: 208-214.
82. Lee CN, Wong KL, Liu JC, Chen YJ, Cheng JT, Chan P. Inhibitory effect of stevioside on calcium influx to produce antihypertension. Plant Med 2001; 67: 796-799.
83. Yasukawa K, Kitanaka S, Seo S. Inhibitory effect of stevioside on tumor promotion by 12-O-tetradeconoylphorbol-13-acetate in two-stage carcinogenesis in mouse skin. Biol Pharm Bull 2002; 25: 1488-1490.
84. Jeppesen PB, Gregersen S, Alstrup KK, Hermansen K. Stevioside induces antihyperglycaemic, insulinotropic and glucogonostatic effects in vivo: studies in the diabetic Goto-Kakizaki (GK) rats. Phytomedicine 2002; 9: 9-14.
85. Chen TH, Chen SC, Chan P, Chu YL, Yang HY, Cheng JT. Mechanism of the hypoglycemic effect of stevioside, a glycoside of Stevia rebaudiana. Planta Med 2005; 71: 108-113.
86. Pezzuto JM, Nanayakkara NP, Compadre CM, Swanson SM, Kinghorn AD, Guenthner TM, Sparnins VL, Lam LK. Characterization of bacterial mutagenicity mediated by 13-hydroxy-ent-kaurenoic acid (steviol) and several structurally-related derivatives and evaluation of potential to induce glutathione S-transferase in mice. Mutat Res 1986; 169: 93-103.
87. Suttajit M, Vinitketkaumnuen U, Meevatee U, Buddhasukh D. Mutagenicity and human chromosomal effect of stevioside, a sweetener from Stevia rebaudiana Bertoni. Environ Health Perspect 1993; 101 (Suppl 3): 53-56.
88. Terai T, Ren H, Mori G, Yamaguchi Y, Hayashi T. Mutagenicity of steviol and its oxidative derivatives in Salmonella typhimurium TM677. Chem Pharm Bull (Tokyo) 2002; 50: 1007-1010.
89. Matsui M, Matsui K, Kawasaki Y, Noguchi T, Kitagawa Y, Sawada M, et al. Evaluation of the genotoxicity of stevioside and steviol using in vitro and one in vivo mutagenicity assays. Mutagenesis 1996; 11: 573-579.
90. Klongpanichpak S, Temcharoen P, Toskulkao C, Apibal S, Glinsukon T. Lack of mutagenicity of stevioside and steviol in Salmonella typhimurium TA 98 and TA 100. J Med Assoc Thai 1997; 80(suppl): S121-S128.
91. Szepesi B, Levin G, Zehner L, Saunders J. Antidiabetic effect of D-tagatose in SHR/N-cp rats. FASEB J 1996; 10: A461.
92. Donner T, Wilber J, Ostrewski D. D-tagatose: a novel therapeutic adjunct for insulin-dependent diabetes. Diabetes 1996; 45 (suppl 2): 125A.
93. Donner TW, Wilber JF, Ostrowski D. D-tagatose: a novel hexose: acute effects on carbohydrate tolerance in subjects with and without type 2 diabetes. Diabetes Obes Metab 1999; 1: 285-291.
94. Donner TW. The metabolic effects of dietary supplementation with D-tagatose in patients with type 2 diabetes. Diabetes 2006; 55(suppl 1): A110; 461P.
95. Levin GV, Zehner LR, Saunders JP, Beadle JR. Sugar substitutes: their energy values, bulk characteristics, and potential health benefits. Am J Clin Nutr 1995; 62 (suppl): 1161S-1168S.
96. Levin GV. Tagatose, the new GRAS sweetener and health product. J Med Food 2002; 5: 23-26.
97. Hoadley JE. The FDA letter of October 25, 1999 to Ms Marsha C. Wertzberger. Available from URT: http://www.fda.gov/ohrms/dockets/dailys/02/Apr02/042302/02p-0177-cp00001-02-Tab-01-vol1.pdf (accessed 5 September, 2007).
98. FDA. Agency response Letter, GRAS Notice No. GRN000078. 2001. Available from URL: http://www.cfsan.fda.gov/~Erdb/opa-g078.html (accesses 5 September, 2007).
99. Bär A. D-tagatose, dossier prepared and submitted by Bioresco on behalf of Arla Food Ingredients amba, Viby, Denmark for evaluation pursuant to EU Novel Foods Regulation (EC) 258/97 by the UK Advisory committee on Novel Foods and Processes, dated August 2, 2004. Available from URL: http://wwwfoodstandards.gov.uk/multimedia/pdfs/tagatoseapplicationdossier.pdf (accessed 5 September, 2007).
100. FSANZ. Final assessment report. Application A472, D-tagatose as a novel food. February 18, 2004. Available from URL: http://www.foodstandards.gov.au/_srcfiles/A472_D_tagatoseFAR.pdf (accessed 5 September, 2007).
101. FSA. A letter from Dr. Chris Jones representing FOOD Standards Agency, UK to Dr. Albert Bär on behalf of Arla Food Ingredients for the approval of tagatose as a novel food ingredient in the European Union, 2005. Available from URL:http://www.food.gov.uk/ multimedia/pdfs/d-tagatoseauthorisation.pdf (accessed 5 September, 2007).
102. Sugirs (Sydney University’s Glycaemic Index Research Service). Glycaemic index Research Report from Arla Foods, Internal Study Report, 2004. Information is available from Spherix Incorporated’s press release of March 26, 2004 entitled “New Study Conforms Low Carb Value of tagatose: Finds Spherix’s Sweetener has a glycaemic and insulin Responses of only 3%.
103. Donner T, Wilber J, Ostrewski D. D-tagatose: a novel therapeutic adjunct for insulin-dependent diabetes. Diabetes 1996; 45 (suppl 2): 125A.
104. Donner TW, Wilber JF, Ostrowski D. D-tagatose: a novel hexose: acute effects on carbohydrate tolerance in subjects with and without type 2 diabetes. Diabetes Obes Metab 1999; 1: 285-291.
105. Buemann B, Tuobro S, Holst JJ, Rehfeld J, Astrup AD. D-tagatose, a stereoisomer of D-fructose, increases blood uric acid concentration. Metabolism 2000; 49: 969-976.
106. Lu Y, Levin GV, Donner TW. Tagatose: a new antidiabetic and obesity control drug. Diabetes, obesity and metabolism 2008; 10: 109-134.
107. Kruger CL, Whittaker MH, Frankos VH. Genotoxicity test on D-tagatose. Regul Toxicol Pharmacol 1999; 29: S36-S42.
108. Kruger CL, Whittaker MH, Frankos VH, Trimmer GW. 990-Day oral toxicity study of D-tagatose in rats. Regul Toxicol Pharmacol 1999; 29: S1-S10.
109. Kruger CL, Whittaker MH, Frankos VH, Schroeder RE. Developmental toxicity study of D-tagatose in rats. Regul Toxicol Pharmacol 1999; 29: S29-S35.
110. Amino Y, Mori K, Tomiyama Y, Sakata H, Fujieda T. Development of a new, low calorie sweetener: new aspartame derivative. In: Deepthi KW, DuBois G (Eds). Sweetness and Sweeteners: Biology, Chemistry and Psychophysics (ACS symposium Series 979). American Chemical Society (ACS), Washington, DC, pp. 463-480.
111. Warrington S, Lee C, Otabe A, Narita T, PoInjak O, Pirags V, Krievins D. Acute and multiple-dose studies to determine the safety, tolerability, and pharmacokinetic profile of advantame in healthy volunteers. Good and Chemical Toxicology 2011; 49: S77-S83.
112. Otabe A, Fujieda T, Masuyama T, Ubukata K, Lee C. Advantame-an overview of its toxicity. Food and Chemical Toxicity 2011; 49: S2-S7.
113. ANZFA, 2001. Inquiry Report and Regulatory Impact Statement, Permission for Use of Neotame. Australia New Zealand Food Authority (ANZFA), 30 May 2001, p. 9.
114. FDA, 2002. Food additive permitted for direct addition to food for human consumption; neotame. Fed Regist 2002; 67 (131), 45300-45310.
115. WHO, 2003. Summary and conclusions, food additives evaluated toxicologically (JECFA/61/SC). Joint FAO/WHO Expert Committee on Food Additives (JECFA), Sixty-first meeting, Rome, 10-19 June 2003. (Toxicological monograph to be published in WHO Food Additives Series No. 52).
116. Mayhew DA, Comer CP, Stargel WW. Food consumption and body weight changes with neotame, a new sweetener with intense taste: differentiating effects of palatability from toxicity in dietary safety studies. Regul Toxicol Pharmacol 2003; 38.
117. Mann SW, Yuschak MM, Amyes SJG, Aughton P, Finn JP. A Combined chronic toxicity/carcinogenecity study of sucralose in Sprague-Dawley rats. Food Chem Toxicol 2000; 38 (suppl 2): S71-S89.
118. Chowaniec J, Hicks RM. Response of the rat to saccharin with particular reference to the urinary bladder. Br J Cancer 1979; 39: 355-375.
119. Schoenig GP, Goldenthal EI, Geil RG, Frith CH, Richter WR, Carlborg FW. Evaluation of the dose response and in utero exposure to saccharin in the rat. Food Chem Toxicol 1985; 23: 475-490.
120. Maone TR, Mattes RD, Bernbaum JC, Beauchamp GK. A new method for delivering a taste without fluids to preterm and term infants. Dev Psychobiol 1990; 23: 179-191.
121. Lindley MG. New developments in low-calorie Sweeteners. World Rev Nutr Diet 1999; 85: 44-51.
122. Hagiwara A, Fukushima S, Kitaori M, Shibata M, Ito N.. Effects of three sweeteners on rat urinary bladder carcinogenesis initiated by N-butyl-N-4hydroxybutyl-nitrosoamine. Gann 1984; 75: 763-768.
123. Ishii H, Incidence of brain tumors in rats fed aspartame. Toxicol Lett 1981; 7: 433-437.
124. Olney JW, Farber NB, Spitznagel E, Robins LN. Increasing brain tumour rates: is there a link to aspartame? J Neuropathol Exp Neurol 1996; 55: 1115-1123.
125. Study E33-34 in Master file 134 on aspartame. On file at the FDA Hearing Clerk’s Office 2001.
126. Anonymous. Aspartame. Review of safety issues. Council on Scientific Affairs. JAMA 1985; 254: 400-402.
127. Gurney JG, Pogoda JM, Holly EA. Aspartame consumption in relation to childhood brain tumor risk: results from a case-control study. [published erratum appears in J Natl Cancer Inst 1997; 89: 1460
128. Gurney JG, Pogoda JM, Holly EA. Aspartame consumption in relation to childhood brain tumor risk: results from a case-control study Natl Cancer Inst 1997; 89: 1072-1074.
129. Ellis JW. “Overview of Sweeteners”. Journal of Chemical Education 1995; 72: 671-675.
130. Australia New Zealand Food Authority (2002) Australia New Zealand Food Standards Code, Standard 1.3.1 Food Additives, Canberra (available at http://www.anzfa.gov.au).
131. Glowaki RC, Hendrick ME, Smiles RE, Torres A. Development and uses of alitame. A novel dipeptide amide sweetener. In Sweeteners, Chapter 5, pp 57-67. Chapter DOI:10.1021/bk-1991-0450.ch005.
132. Fischer DO, Laitwaite BS., Butler BT, Coleman DV, Levinsky HV, Ochoa R, et al. Two year oncogenicity study with dietary administration and In Utero Exposure in Sprague-Dawley rats. Unpublished Report no 90-444-20 from Pfizer Central research, Groton, CT, USA. Submitted to WHO by Pfizer INC. Groton, CT, USA.
133. FDA (Food and Drug Administration). Food additives permitted for direct addition to food for human consumption: acesulfame potassium. Final rule. Fed Reg 1988; 53: 28379.
134. FDA (Food and Drug Administration). Food additives permitted for direct addition to food for human consumption: acesulfame potassium. Final rule. Fed Reg 1998; 63: 36344-36361.
135. Jung R, Kreiling R, Mayer DG., Acesulfame K. Edited by D.G. Mayer and F.H. Kemper. 1991; pp.87-104. Marcel Dekker, New York.
136. Malaisse WJ, Vanonderbergen A, Louchami K, Jijakli H, Malaisse-Lagae F. Effect of artificial sweeteners on insulin release and cationic fluxes in rat pancreatic islets. Cell Signal 1998; 10: 727-733.
137. Sandy MS. Letter from MS Sandy, California Office of Environment Health Hazard Assessment, California Environment Protection Agency, to K Olden, National Toxicology Program/National Institute of Environment Health Sciences. GMM tests of aspartame and acesulfame, 16 May 2003.
138. NTP Toxicity Studies of acesulfame Potassium (CAS No. 55589-62-3) in FVB/N-TgN(v-Ha-ras)led (Tg AC) Hemizygous Mice and Carcinogenecity Studies of acesulfame potassium in B6129-Trp53m1Brd(N5) Haploinsufficient Mice (Feed Studies). NTP MMM2 Research Triangle Park National Toxicology Program, 2005. Available http://ntp.niehs.nih.gov/files/GMM2_Web.pgf [Assessed 10 July 2006).
139. Bopp BA, Sonders RC, Kesterson JW. Toxicological aspects of cyclamate and cyclohexylamine. Crit Rev Toxicol 1986; 16:213-306.
140. Anonymous. FDA extends ban on cyclamates. Science 1970; 169: 962.
141. Wagner MW. Cyclamate acceptance. Science 1970; 168: 1605.
142. Renwick AG. The metabolism of intense sweeteners. Xenobiotics 1986; 16: 1057-1071.
143. Gaunt IF, Sharratt M, Grasso P, Lansdown AB, Gangolli SD.. Short-term toxicity of cyclohexylamine hydrochloride in the rat. Food Cosmet Toxicol 1974; 12: 609-624.
144. James RW, Heywood R, Crook D. Testicular responses of rats and dogs to cyclohexylamine overdosage. Food Cosmet Toxicol 1981; 19: 291-296.
145. Roberts A, Renwick AG, Ford G, Creasy DM, Gaunt I. The metabolism and testicular toxicity of cyclohexylamine in rats and mice Toxicol Appl Pharmacol 1989; 98: 216-229.
146. Takayama S1, Renwick AG, Johansson SL, Thorgeirsson UP, Tsutsumi M, Dalgard DW, et al. Long-term toxicity and carcinogenecity study of cyclamate in nonhuman primates. Toxicol Sci 2000; 53: 33-39.
147. Huff J, Tomatis L. Re: Long-term toxicity and carcinogenecity of cyclamate in nonhuman primates. (Takayama. Toxicol Sci. 53: 33-39).
148. Huff J, Tomatis L. Re: Long-term toxicity and carcinogenecity of cyclamate in nonhuman primates. Toxicol Sci 2000; 57: 186.
149. JECFA. Toxicological evaluation of certain food additives. WHO Food additive Series, No 17. (Twenty- sixth report of the Joint FAO/WHO Expert Committee on Food Additives. WHO Technical Report Series, No. 683). http://www.who.int/pcs/jecfa/JECFA-publications.htm.
150. Bloomgarden ZT. Nonnutritive sweeteners, fructose, and other aspects of diet. Diabetes Care 2011; 34: e46-e51.
151. Ferder L, Ferder MD, Inserra F. The role of high-fructose corn syrup in metabolic syndrome and hypertension. Curr Hypertens Rep 2010; 12: 105-1012.
152. Tappy L. Q&A: ‘toxic’ effects of sugar: should we be afraid of fructose? BMC Biol 2012; 10: 42.
153. Miller A, Adeli K. Dietary fructose and the metabolic syndrome. Curr Opin Gastroenterol 2008; 24: 204-209.
154. Tran LT, Yuen VG, McNeill JH. The fructose-fed rat: a review on the mechanism of fructose-induced insulin resistance and hypertension. Mol Cell Biochem 2009; 332: 145-159.
155. Bray GA, Nielsen SJ, Popkin BM. Consumption of high-fructose corn syrup in beverages may play a role in the epidemic of obesity. Am J Clin Nutr 2004; 79: 537-543.
156. Lê KA1, Ith M, Kreis R, Faeh D, Bortolotti M, Tran C, Boesch C, Tappy L. Fructose overconsumption causes dyslipidaemia and ectopic lipid deposition in healthy subjects with and without a family history of type 2 diabetes. The Am J Clin Nutr 2009; 89: 1760-1765.
157. Stanhope KL, Havel PJ. Fructose consumption: considerations for future research on its effects on adipose distribution, lipid metabolism, and insulin sensitivity in humans. J Nutr 2009; 139: 1236S-1241S.
158. Axelsen LN, Lademann JB, Petersen JS, et al. Cardiac and metabolic changes in ling-term high fructose-fat fed rats with severe obesity and extensive intramyocardial lipid accumulation. Am J Physiol Regul Intergr Comp Physiol 2010; 298: R1560-R1570.
159. Barros CM1, Lessa RQ, Grechi MP, Mouço TL, Souza Md, Wiernsperger N, Bouskela E.. Substitution of drinking water by fructose solution induces hyperinsulinemia and hyperglycemia in hamsters. Clinics 2007; 62: 327-334.
160. Wei Y, Wang D, Topczewski F, Pagliassotti M. Fructose-mediated stress signaling in the liver. Implications for hepatic insulin resistance. The J Nutr Biochem 2007; 18: 1-9.
161. Dolan LC, Potter SM, Burdock GA, Evidence-based review on the effect of normal dietary consumption of fructose on development of hyperlipidaemia and obesity in healthy, normal weight individuals. Crit Rev Sci Nutr 2010; 50: 53-84.
162. Tappy L, Lê KA, Tran C, Paquot N. Fructose and metabolic diseases: new findings, new questions. Nutrition 2010; 26: 1044-1049.